{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-023808","form_type":"8-K","ticker":"ABCL","cik":"0001703057","company_name":"AbCellera Biologics Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.398894+00:00","generated_at":"2026-05-22T04:52:45.451050+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"AbCellera Q1 revenue down 58% to $4.2M; net loss $45.6M; introduces ABCL635 for hot flashes","bullets":["Total revenue $4.2M, down 58% from $10.0M in Q1 2024.","Net loss $45.6M ($0.15/share) vs net loss $40.6M ($0.14) year ago.","Announces ABCL635, a first-in-class NK3R antibody for vasomotor symptoms from menopause; Phase 1 expected H2 2025.","Available liquidity ~$810M ($633M cash + $178M government funding).","Cumulative partner program starts 97, clinic molecules 16; R&D spend up to $42.5M."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-023808","json":"https://secwatch.observer/filing/0001628280-25-023808.json","markdown":"https://secwatch.observer/filing/0001628280-25-023808.md","text":"https://secwatch.observer/filing/0001628280-25-023808.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703057/000162828025023808/0001628280-25-023808-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703057/000162828025023808/abcl-20250508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T04:52:45.451050+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}